Skip to main content

Mission Investments

A A

The Australian Government and Mission Funding Partners have awarded a total of $50.16 million to Medical Research Future Fund (MRFF) initiatives under the Mission:

Initiative

Institution

Commitment (million)

Zero Childhood Cancer Initiative

University of New South Wales

$5.00

Australian and New Zealand Children’s Haematology/Oncology Group (ANZCHOG)

Monash University

$2.50

Australian and New Zealand Children’s Haematology/Oncology Group (ANZCHOG)

Monash University (co-funded with Financial Markets Foundation for Children, the Robert Connor Dawes Foundation and Carrie’s Beanies 4 Brain Cancer)

$7.16

Cooperative Trials Group for Neuro-Oncology (COGNO)

University of Sydney

$2.50

COZMOS: Phase I/Ib trial of COmbined 5'-aZacitidine and carboplatin for recurrent/refractory paediatric brain and solid tuMOurs

Monash University (co-funded with Carrie’s Beanies 4 Brain Cancer)

$0.25

SJ-ELiOT: St Jude - Phase 1 Evaluation of LY2606368, molecularly-targeted CHK1/2i Therapy, in combination with cyclophosphamide or gemcitabine for children and adolescents with refractory or recurrent medulloblastoma brain tumours

Monash University (co-funded with Carrie’s Beanies 4 Brain Cancer)

$0.45

MAGMA: Multi-Arm GlioblastoMa Australasia Trial

University of Sydney (co-funded with Carrie’s Beanies 4 Brain Cancer and the Mark Hughes Foundation)

$2.42

PICCOG: PARP and Immune Checkpoint inhibitor COmbination for relapsed IDH-mutant high-grade Glioma

University of Sydney

$1.39

FET-PET in Glioma (FIG Study) 

La Trobe University

$1.25

LUMOS: Low & intermediate grade glioma umbrella study of molecular guided therapies

University of Sydney

$0.50

Role of the NKp44-PDGF-DD axis in glioblastoma

University of Melbourne

$0.57

PARC: A Phase I/II study evaluating the safety and activity of pegylated recombinant human arginase (BCT-100) relapsed/refractory cancers of children and young adults

Monash University

$0.48

Targeted invadapodia to treat glioblastomas

University of Melbourne

$0.38

BRAIN: Brain cancer Rehabilitation, Assessment, Intervention of survivor Needs

University of Sydney

$4.97

A new nurse-led intervention to re-engage childhood brain cancer survivors

University of New South Wales

$1.94

Responding to need: technology-enhanced brain cancer survivorship

University of Melbourne

$2.62

MET-MED Trial: A phase III randomised double-blind placebo-controlled trial of metformin for cognitive recovery and white matter growth in paediatric medulloblastoma patients

Monash University

$0.88

CONNECT 1903: A pilot and surgical study of larotrectinib for disease control in children with newly-diagnosed high-grade glioma with NTRK fusion

Monash University

$0.32

LOGGIC: A phase III, randomised international multi-centre trial for LOw Grade Glioma In Children and adolescents

University of New South Wales

$1.13

LUMOS: Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided TherapieS

University of Sydney

$1.98

GLIMMER: Glioma Liquid biopsy and Multiomic-Monitoring Enabled Research platform

The Walter and Eliza Hall Institute of Medical Research

$4.55

A new targeted combination therapy with matched biomarker to treat intractable glioblastoma

University of New South Wales

$0.58

“Off-the-shelf” CAR-T cell immunotherapy for brain cancer

The Council of the Queensland Institute of Medical Research

$0.33

Supporting Australian Brain Cancer Research with an integrated network of platforms

University of Sydney

$5.99

 

In addition to co-funding MRFF opportunities, Mission Funding Partners have committed $59.54 million in initiatives under the Mission that are funded and managed independently.

Page last updated on 16 May 2023